Renal transplantation in high-risk patients

Drugs

Volumn 67, Issue 11, 2007, Pages 1603-1627

  Weimert, Nicole A ^a   Alloway, Rita R ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANAPHYLAXIS; ANTIBODY DETECTION; BLOOD GROUP ABO SYSTEM; CADAVER DONOR; CHILL; CLINICAL TRIAL; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; LYMPHOCYTOPENIA; NEPHROTOXICITY; PLASMAPHERESIS; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; TISSUE TYPING;

AGE FACTORS; CONTINENTAL POPULATION GROUPS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 34547957878     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767110-00005     Document Type: Review

References (136)

1. Ferguson RM, Henry ML, Elkhammas EA, et al. Twenty years of renal transplantation at Ohio State University: the results of five eras of immunosuppression. Am J Surg 2003; 186: 306-11
2. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993-5
3. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289
4. Almond PS, Matas AJ, Gillingham KJ, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-8
5. Gulanikar AC, MacDonald AS, Sunguretkin U, et al. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323-7
6. Troppmann C, Gilligham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcomes after cadaver renal transplantation. Transplantation 1995; 59: 962-8
7. Kaplan B, Meier-Kriesche HU. Renal transplantation: a half century of success and the long road ahead. J Am Soc Nephrol 2004; 15: 3270-1
8. Swanson SJ, Hypolite IO, Agodoa LYC, et al. Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant 2002; 2: 65-75
9. 2005 Annual report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1995-2004. Rockville (MD): Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; Richmond (VA): United Network for Organ Sharing; Ann Arbor (MI): Arbor Research Collaborative for Health, 2005
10. Tullius SG, Reutzel-Selke A, Nieminen-Kelha M, et al. Contribution of donor age and ischemic injury in chronic renal allograft dysfunction. Transplant Proc 1999; 31: 1298-9
11. Gaston RS, Deierhoi MH, Young CJ, et al. "High-risk" renal transplantation: evolving definitions at a single center. Clin Transpl 2004: 121-6
12. D'Alessandro AM. Current results of an organ procurement organization effort to increase utilization of donors after cardiac death. Transplantation 2006; 81: 15
13. Brook NR, White SA, Waller JR, et al. Non-heart beating donor kidneys with delayed graft function have superior graft survival compared with conventional heart-beating donor kidneys that develop delayed graft function. Am J Transplant 2003; 3: 614-8
14. Sanchez-Frutuoso AL, Prats D, Torrente J, et al. Renal transplantation from non-heart beating donors: a promising alternative to enlarge the donor pool. J Am Soc Nephrol 2000; 11: 350-8
15. Tullius SG, Reutzel-Selke A, Egermann F, et al. Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction. J Am Soc Nephrol 2000; 11: 1317-24
16. Waiser J, Schreiber M, Budde K, et al. Age matching in renal transplantation. Nephrol Dial Transplant 2000; 15: 696-700
17. Racusen LC. Antibody-mediated rejection in the kidney. Transplant Proc 2004; 36: 768-9
18. Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the Antibody Working Group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181-5
19. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-14
20. Shah A, Nadasdy T, Arend L, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004; 77: 1399-405
21. Crespo M, Pascual M, Tolkoff-Rubin N, et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology, and clinical characteristics. Transplantation 2001; 71: 652-8
22. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmaphersis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-95
23. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-29
24. Davis CL. Transplant: immunology and treatment of rejection. Am J Kidney Dis 2004; 43: 1117-23
25. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-23
26. Almond PS, Matas AJ, Gillingham KJ, et al. Risk factors for second renal allografts immunosuppressed with cyclosporine. Transplantation 1991; 52: 253-8
27. Zaltzman JS, Boucher A, Busque S, et al. A prospective 3 yr evaluation of tacrolimus based immunosuppressive therapy in immunological high risk renal allograft recipients. Clin Transplant 2005; 19: 26-32
28. Bryan CF, Luger AM, Martinez J, et al. Cold ischemia time: an independent predictor of increased HLA class I antibody production after rejection of a primary cadaveric renal allograft. Transplantation 2001; 71: 875-9
29. 2004 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1994-2003. Rockville (MD): Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; Richmond (VA): United Network for Organ Sharing; Ann Arbor (MI): University Renal Research and Education Association, 2004
30. Sanfilippo F, Vaughn WK, Bollinger RR, et al. Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitization and renal transplant results. Transplantation 1982; 34: 360-6
31. Swaminathan S, Lager DJ, Qian X, et al. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006; 21: 2607-14
32. Briganti E, Russ G, McNeil J, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-9
33. Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal allograft Disease Registry. Transplantation 1999; 68: 635-41
34. Ibrahim H, Rogers T, Casingal V, et al. Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. Transplantation 2006; 81: 214-9
35. Pozzi C, Bolasco P, Fogazzi G, et al. Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancet 1999; 353: 883-7
36. United Network for Organ Sharing. Policies and bylaws [online]. Available from URL: http://www.unos.org/policiesandbylaws/policies.asp [Accessed 2007 May 23]
37. Reid ME, Olsson ML. Human blood group antigens and antibodies. In: Hoffman R, Benz EJ, editors. Hematology: basic principles and practice. 4th ed. Philadelphia (PA): WB Saunders, 2005: 2370-4.
38. Norman DJ, Prather JC, Alkhunaizi AM, et al. Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade. Transplant Proc 2001; 37: 3327-30
39. Aikawa A, Yamashita M, Hadano T, et al. ABO incompatible kidney transplantation: immunological aspect. Exp Clin Transplant 2003; 1: 112-8
40. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-9
41. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998; 59: 313-22
42. Wahrmann M, Exner M, Haidbauer B, et al. [C4d]FlowPRA screening: a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 2005; 66: 526-34
43. Felgar RE, Ryan DH. Automated analysis of blood cells. In: Hoffman R, Benz EJ, editors. Hematology: basic principles and practice. 4th ed. Philadelphia (PA): WB Saunders, 2005: 2677-84
44. Cicciarelli J, Helstab K, Mendez R. Flow cytometry PRA, a new test that is highly correlated with graft survival. Clin Transplant 1992; 6: 159-64
45. Chandraker A, Perkins DL, Carpenter CB, et al. Transplantation immunobiology. In: Brenner BM, editor. Brenner and Rector's the kidney. 7th ed. Philadelphia (PA): WB Saunders, 2004: 2766-67
46. Keith DS, deMattos A, Golconda M, et al. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 2005; 16: 1512-21
47. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney tranplants. N Engl J Med 1994; 331: 765-70
48. Takemoto SK, Terasaki PI, Gjertson DW, et al. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078-84
49. Ting A, Edwards LB. Human leukocyte antigen in the allocation of kidneys from cadaveric donors in the United States. Transplantation 2004; 77: 610-4
50. Roberts JP, Wolfe RA, Bragg-Gersham JL, et al. Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 2004; 350: 545-51
51. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contradiction vs risk. Am J Transplant 2003; 3: 1488-500
52. Piatosa B, Rubik J, Grenda R. Is positive flow cytometric crossmatch a risk factor for early cadaveric kidney graft dysfunction? Transplant Proc 2006; 38: 53-5
53. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int 2006; 19: 87-97
54. Clark B, Cole JY, Wortley A, et al. Intravenous immunoglobulin-induced panel reactive antibody A reduction: not all preparations are created equal. Transplantation 2003; 75: 242-5
55. Mackay IR, Rosen FS. Immunomodulation of autoimmune and inflammatory disease with intravenous immune globulin. N Engl J Med 2001; 345: 747-55
56. Lam L, Whitsett CF, McNicholl JM, et al. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993; 342: 678
57. Akalin E, Bromberg JS. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005; 66: 359-63
58. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 Trial. J Am Soc Nephrol 2004; 15: 3256-62
59. Lemm G. Composition and properties of IVIG preparations that affect tolerability and therapeutic efficacy. Neurology 2002; 59 Suppl.: S28-32
60. Itkin YM, Trujillo TC. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy 2005; 25: 886-92
61. Glotz D, Haymann JP, Sansonetti N. Suppression of HLA-specific alloantibodies by high dose intravenous immunoglobulins (IvIg): a potential tool for transplantation of immunized patients. Transplantation 1993; 56: 335-7
62. Goltz D, Antoine C, Pierre J, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIG). Am J Transplant 2002; 2: 758-60
63. Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 1614-6
64. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531-6
65. Thielke J, DeChristopher PJ, Sankary H, et al. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc 2005; 37: 643-4
66. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloanibody. Am J Transplant 2006; 6: 346-51
67. Saito K, Nakagawa Y, Suwa M, et al. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006; 13: 111-7
68. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001
69. Sawada T, Fuchinoue S, Kawase T, et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18: 254-60
70. Rituxan (rituximab) [package insert]. South San Francisco (CA): Genentech, Inc. Last updated: Feb 2006
71. Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293: 1883-90
72. Keith DS, Demattos A, Golconda M, et al. Effect of donor recipient age match on survival after first deceased donor renal transplantation. J Am Soc Nephrol 2004; 15: 1086-91
73. Young CJ, Gaston RS. Renal transplantation in Black Americans. N Engl J Med 2000; 343: 1545-52
74. Gaston RS, Ayres I, Dooley LG, et al. Racial equity in renal transplantation: the disparate impact of HLA-based allocation. JAMA 1993; 270: 1352-6
75. Tankersley MR, Gaston RS, Curtis JJ, et al. The living donor process in kidney transplantation: influence of race and comorbidity. Transplant Proc 1997; 29: 3722-3
76. Cooper TY, Jordan CL, Willimon CM, et al. Comparison of panel reactive antibody levels in Caucasians and African American renal transplant candidates. Transplantation 1995; 60: 327-30
77. Mange KC, Prak EL, Kamoun M, et al. Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function. Kidney Int 2004; 66: 1187-92
78. Akalin E, Neylan JF. The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation 2003; 75: 1496-500
79. Moore DE, Feurer ID, Rodgers S, et al. Is there racial disparity in outcomes after solid organ transplantation? Am J Surg 2004; 188: 571-4
80. Foster CE, Philosophe B, Schweitzer EJ, et al. A decade of experience with renal transplantation in African-Americans. Ann Surg 2002; 236: 794-804
81. Hariharan S, Schroeder TJ, First MR. Effect of race on renal transplant outcome. Clin Transplant 1993; 7: 234-9
82. Ojo AO, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66: 1651-9
83. Gaston RS, Benfield M. The relationship between ethnicity and outcomes in solid organ transplantation. J Pediatr 2005; 147: 721-3
84. Hutchings A, Benfield MR. Increased costimulatory responses in African-American kidney allograft recipients. Transplantation 2001; 71: 692-5
85. Press R, Carrasquillo O, Nickolas T, et al. Race/ethnicity, poverty status, and renal transplant outcomes. Transplantation 2005; 80: 917-24
86. Walczak DA, Calvert D, Jarzembowski TM, et al. Increased risk of post-transplant diabetes mellitus despite early steroid distibody. continuation in Hispanic kidney transplant recipients. Clin Transplant 2005; 19: 527-31
87. Sequist TD, Narva AS, Stiles SK, et al. Access to renal transplantation among American Indians and Hispanics. Am J Kidney Dis 2004; 44: 344-52
88. Weber LT, Shipkova M, Armstrong VW, et al. The pharmaco-kinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil Therapy. J Am Soc Nephrol 2002; 13: 759-68
89. Montini G, Ujka F, Varagnolo C, et al. The pharmacokinetics and immunosuppressive response of tacrolimus in pediatric renal transplant recipients. Pediatr Nephrol 2006; 21: 719-24
90. Hwang AH, Cho YW, Cicciarelli J, et al. Risk factors for short-and long-term survival of primary cadaveric renal allografts in pediatric recipients: a UNOS analysis. Transplantation 2005; 80: 466-70
91. Rianthavorn P, Ettenger RB. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint. Pediatr Transplant 2005; 9: 398-407
92. Danovitch G, Savransky E. Challenges in the counseling and management of older transplant candidates. Am J Kidney Dis 2006; 47 Suppl.: S86-97
93. Hansberry MR, Whittier WL, Krause MW. The elderly patient with chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 71-7
94. Ojo AO, Hanson JA, Meier-Krriesche HU, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait listed candidates. J Am Soc Nephrol 2001; 12: 589-97
95. Madden RL, Munda R, Hariharan S, et al. Outcome of cadaver kidneys using non-ideal donors. Transplant Proc 1993; 25: 1568-9
96. Battaglia M, Ditonna P, Selvaggio O, et al. Medical and surgical complications after kidney transplantation from "suboptimal donors": one center's experience. Transplant Proc 2004; 36: 493
97. Whiting JF, Zavala EY, Alexander JW, et al. The cost-effectiveness of transplantation with expanded donor kidneys. Transplant Proc 1999; 31: 1320-1
98. McKay DB, King AJ. Donor and recipient issues in renal transplantation. In: Brenner BM, editor. Brenner and Rector's the kidney. 7th ed. Philadelphia (PA): Saunders, 2004: 2797-800
99. Ramos E, Aoun S, Harrmon WE. Expanding the donor pool: effect on graft outcome. J Am Soc Nephrol 2002; 13: 2590-9
100. Stratta RJ, Rohr MS, Sundberg AK, et al. Intermediate term outcomes with expanded criteria for deceased donors in kidney transplantation: a spectrum or specter of quality? Ann Surg 2006; 243: 594-603
101. Nyberg SL, Matas AJ, Rogers M, et al. Donor scoring system for cadaveric renal transplantation. Am J Transplant 2001; 1: 162-70
102. Port FK, Bragg JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281-6
103. Ethics Committee American College of Critical Care Medicine, Society of Critical Care Medicine. Recommendations for non-heartbeating organ donation. Crit Care Med 2001; 29: 1826-31
104. Loverre A, Ditonno P, Crovace A, et al. Ischemia-reperfusion injury induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J Am Soc Nephrol 2004; 15: 2675-86
105. Irish WD, Mccollum DA, Tesi RJ, et al. Nomogram for predicting the likelihood for delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967-74
106. Weber M, Dindo D, Demartines N, et al. Kidney transplantation from donors without a heartbeat. N Engl J Med 2002; 347: 248-55
107. Keith DS, deMattos A, Golconda M, et al. Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol 2005; 16: 1512-21
108. Bunnapradist S, Takemoto SK. Multivariate analysis of antibody induction therapy and their associated outcomes in decreased donor transplants. Transplant Proc 2005; 37: 889-91
109. Brennan DC, Agha I, Bohl DL, et al. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-8
110. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78: 136-41
111. Boletis J, Balitsari A, Filiopoulos V, et al. Delayed renal graft function: the influence of immunosuppression. Transplant Proc 2005; 37: 2054-9
112. Beiras-Fernandez A, Chappell D, Hammer C, et al. Influence of polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury in a non-human primate model. Transpl Immunol 2006; 15: 273-9
113. Charpentier B, for the European Tacrolimus versus Miscroimulsified Cyclosporine Group. A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. Transplant Proc 2002; 34: 1625-6
114. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005; 5: 2740-4
115. Thymoglobulin (Anti-thymocyte globulin [rabbit]) [package insert]. Genzyme Polyclonals SAS Lyons, France. Revision 6, 2005
116. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-76
117. Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipients. Transplantation 2005; 79: 716-21
118. Bloom DD, Hu H, Fechner JH, et al. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81: 81-7
119. Alemtuzumab (Campath) [package insert]. Genzyme Corporation, Cambridge (MA). Last updated: July 2005
120. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 2003; 76: 120-9
121. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009-14
122. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765-74
123. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426-33
124. Watson WJE, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005; 5: 1347-53
125. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction. Long-term results. Am J Transplant 2005; 5: 2539-48
126. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-15
127. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136: 754-60
128. Hrilick DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant 2002; 2: 19-24
129. Almawi WY, Hardo ET, Strom TB. Evidence that glucocorticosteroid-mediated immunosuppressive effects do not involve altering second messenger function. Transplantation 1991; 52: 133-40
130. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta analysis. J Am Soc Nephrol 1993; 4: 1300-5
131. Cohen DJ, Loertscher R, Rubin MF, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984; 101: 667-82
132. European Multicenter Trial Group. Cyclosporine in cadaveric renal transplantation: one year follow-up of a multicenter trial. Lancet 1983; II: 986-9
133. Starzl TE, Hakala TR, Rosenthal JT, et al. The Colorado-Pittsburgh cadaveric renal transplantation study with cyclosporine. Transplant Proc 1983; 15: 2459-62
134. McTaggart RA, Tomlanovic S, Bostrom A. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004; 78: 475-80
135. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 1277-82
136. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003; 3: 1581-6